The use of peptides as therapeutics has often been associated with several drawbacks such
as poor absorption, low stability to proteolytic digestion, and fast clearance. Peptidomimetics …

Protein-protein interactions (PPIs) are well-established as a class of promising drug targets
for their implications in a wide range of biological processes. However, drug development …

Cyclic peptides are among the most diverse architectures for current drug discovery efforts.
Their size, stability, and ease of synthesis provide attractive scaffolds to engage and …

Nature has developed a plethora of protein machinery to operate and maintain nearly every
task of cellular life. These processes are tightly regulated via post‐expression modifications …

Peptide display technologies are a powerful method for discovery of new bioactive
sequences, but linear sequences are often very unstable in a biological setting …

Protein–protein interactions (PPI) are involved in all cellular processes and many represent
attractive therapeutic targets. However, the frequently rather flat and large interaction areas …

Technological advances and breakthrough developments in the pharmaceutical field are
knocking at the door of the “undruggable” fortress with increasing insistence. Notably, the …

Intracellular protein–protein interactions (PPIs) are challenging targets for traditional drug
modalities. Macrocyclic peptides (MPs) prove highly effective PPI inhibitors in vitro and can …

The use of antibiotics is threatened by the emergence and spread of multidrug-resistant
strains of bacteria. Thus, there is a need to develop antibiotics that address new targets. In …

The development of potent, specific, and pharmacologically viable chemical probes and
therapeutics is a central focus of chemical biology and therapeutic development. However, a …